| CASE REPORT |
|
| Year : 2020 | Volume
: 57
| Issue : 4 | Page : 467-469 |
5-Fluorouracil induced extravasation injury
Sangana Sunitha Reddy1, Shalaka Somayaji1, Mamatha Krishna Murthy1, Vinayak V Maka2
1 Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangaluru, Karnataka, India
2 Department of Medical Oncology, M.S. Ramaiah Medical College and Hospitals, Bengaluru, Karnataka, India
Correspondence Address:
Mamatha Krishna Murthy
Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangaluru, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijc.IJC_281_19
Antineoplastic drugs based on their ability to cause local damage are classified as irritants, vesicants, and non-vesicants. Previous literature has reported higher rate of vesicants induced extravasation (EV) compared to irritants. We report the first case of irritant, 5-fluorouracil causing grade III EV in 55-year-old woman. The patient was diagnosed with esophageal squamous cell carcinoma. Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) chemotherapy regimen was planned and administered through peripheral venous access. Patient experienced grade 3 extravasation in her 3rd cycle following 5-fluorouracil (5-FU) administration. The suspected drug was withdrawn immediately and discontinued from the 4th cycle of the regimen. The patient completely recovered from the symptoms of pain and erythema in the next cycle and care was taken not to infuse drug in the same site again. Since there is no appropriate antidote available to manage this condition, measures need to be taken to identify the predisposing factors for EV and prevent them.
[FULL TEXT] [PDF]*
|
